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isBackground: The safety issues regarding foods derived from
genetically modified (GM) plants are central to their
acceptance into the food supply. The potential allergenicity
of proteins newly introduced in GM foods is a major safety
concern.
Objective: We sought to monitor, in potentially sensitive
human populations, the allergenicity effects of 5 GM
materials obtained from sources with no allergenic potential
and already under commercialization in the European Union.
Methods: We have performed skin prick tests with protein
extracts prepared from transgenic maize (MON810, Bt11, T25,
Bt176) and soya (Roundup Ready) samples and from
nontransgenic control samples in 2 sensitive groups: children
with food and inhalant allergy and individuals with asthma-
rhinitis. We have also tested IgE immunoblot reactivity of sera
from patients with food allergy to soya (Roundup Ready) and
maize (MON810, Bt11, Bt176) samples, as well as to the pure
transgenic proteins (CryIA[b] andCP4 5-enolpyruvylshikimate-
3-phosphate synthase).
Results: None of the individuals undergoing tests reacted
differentially to the transgenic and nontransgenic samples
under study. None of the volunteers tested presented detectable
IgE antibodies against pure transgenic proteins.
Conclusion: The transgenic products under testing seem to be
safe in terms of allergenic potential. We propose postmarket
testing as an important screening strategy for putative allergic
sensitization to proteins introduced in transgenic plants.
(J Allergy Clin Immunol 2005;116:403-10.)
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doi:10.1016/j.jaci.2005.04.014Recombinant DNA technology or genetic engineering
allows the transfer of single genes from one organism to
another, even if distantly related, a feat impossible through
conventional plant breeding. As a result, a genetically
modified organism (GMO) will contain a modified or
additional trait encoded by the introduced gene or genes,
which generally results in additional proteins.
Potential benefits for world agriculture derived from
GMOs could be enormous, including the possibility of
producing higher yields of more nutritious food in more
sustainable regimens.1-5
With the development of the new modification tech-
niques, there is the increasing concern of emergence of
new food allergies. An example of such a situation is the
Brazil nut allergen (2S protein), which when overex-
pressed in soybean was found to retain its allergenicity
and was therefore never commercialized.6
Food allergy is a term that should be used to describe
adverse reactions to certain foods because of immunologic
mechanisms.7Themajority of individualswithdocumented
immunologic reactions to foods exhibit IgE-mediated
hypersensitivity reactions that can be sudden, severe, and
life-threatening.8 The best estimates are that IgE-mediated
food allergies affect approximately 1% to 2% of the adult
population9,10; in children this value is estimated to be2%to
8%.11,12
Before market introduction, genetically modified (GM)
food products are subjected to extensive assessment of
potential effects to human health, including toxicity and
potential allergenicity. When the gene source is an aller-
genic food, in vitro and clinical tests are available to assess
the allergenicity of the transferred protein or proteins.
However, most genes transferred through genetic engi-
neering are obtained from organisms with no allergenic
history. In such cases the assessment of allergenicity
becomes more difficult to obtain because of the absence of
valid methods and models.13-16
Abbreviations used
Bt: Bacillus thuringiensis
EPSPS: 5-Enolpyruvylshikimate-3-phosphate synthase
GM: Genetically modified
GMO: Genetically modified organism
PAT: Phosphinotricine acetyl transferase
RUR: Roundup Ready
SPT: Skin prick test403
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isTABLE I. Transgenic flour products tested in SPTs and in IgE Immunoblot reactivity assays
Material Characteristics
Date of
commercialization
Responsible
company
Origin and
certification of
the material
Method of testing
and human
population studied
2% GM
Bt11 maize
Insect resistance (CryIA[b]
gene) and ammonium
glufosinate tolerance
(PAT gene); 35S pro;
NOS 3# t
1998 Syngenta Institute of Reference
Materials and
Measurements
certified
SPTs in a population
of allergic children
(27 individuals);
IgE immunoblot
reactivity assay with sera
from patients with food
allergy (57 individuals)
100% GM
Bt176 maize
Insect resistance (CryIA[b]
gene) and ammonium
glufosinate tolerance
(PAT gene); 35S pro; 35S t
1997 Syngenta
National Service of
Plant Protection
(DGPC); not certified
SPTs in a population
of allergic children
(27 individuals);
IgE immunoblot
reactivity assay with
sera from patients
with food allergy
(57 individuals)
100% GM
T25 maize
Ammonium glufosinate
tolerance (PAT gene);
35S pro; 35S t
1998 Bayer Crop
Sciences
SPTs in a population of
patients with asthma-
rhinitis (50 individuals)
100% GM
MON810
maize
Insect resistance (CryIA[b]
gene); 35S pro; NOS3# t
1998 Monsanto SPTs in a population
with asthma-rhinitis
(50 individuals); IgE
immunoblot reactivity
assay with sera from
patients with food allergy
(24 of the 57 individuals)
5% GM
RUR soya
Gliphosate resistance
(CP4EPSPS gene);
35S pro; NOS 3# t
1996 Monsanto Institute of Reference
Materials and
Measurements
certified
SPTs in a population of
allergic children (27
individuals); IgE
immunoblot reactivity
assay with sera from
patients with food allergy
(57 individuals)
35S pro, 35S Cauliflower Mosaic Virus promoter; 35S t, 35S Cauliflower Mosaic Virus terminator; NOS 3# t, Agrobacterium tumefaciens nopaline synthase
terminator; DGPC, Direccxao Geral de Proteccxa˜o de Culturas.In this study we have monitored the IgE response of
allergy-sensitive populations to GM maize and soya
products (Table I). The transgenes in maize and soya
were obtained from sources with no allergenic history and
approved for human consumption in the European Union.
The IgE response of the same individuals to nonmodified
products was also analyzed for comparison.
METHODS
This study was evaluated and approved by the Research Ethic
Committees of the Hospital of Santa Maria and the National Institute
of Health, Lisbon, Portugal. All individuals participating in this study
or their parents also provided informed consent.
Food inquiry
Because of the fact that IgE-mediated allergic reactions require
prior exposure, resulting in sensitization, we have performed a food
inquiry to evaluate the consumption of soya and maize food-derived
products. Bearing in mind that since 1998 all the GM products
under testing were approved for commercialization in the European
Union (Table I), we assumed that consumption of maize and soyafood-derived products implied a consumption of GM soya and
maize.
The food inquiry was performed on 106 healthy volunteers to find
out which maize- and soya-derived products (from a list of 205 dif-
ferent products) they had already consumed. The population studied
included individuals with ages from 1 to 41 years, with an average of
12.4 years (48 male and 58 subjects).
Transgenic quality of the noncertified
flour samples
In addition to the 3 noncertified transgenic products listed in
Table I, nontransgenic analogues were also tested as controls. For
the noncertified material (Table I), we have first confirmed the
transformation event and the absence of cross-contamination among
them.
For these analyses, DNAwas isolated by using the cetyltrimethyl-
ammonium bromide method,17 with 3 replicas per sample. DNA
quality and concentration were analyzed by means of agarose gel
electrophoresis, and maize-specific amplifiable DNA was detected
by using PCR amplification of a 226-bp sequence from the maize
invertase gene.18
The presence or absence of the 35S Cauliflower Mosaic Virus
promoter in the transgenic (Table I) and control samples was checked
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sequence.18
Transformation event–specific PCR reactions were performed to
verify the presence of MON810, T25, and Bt176 transgenic events.18
Different internal controls were always used to detect putative
contaminations. In each case whole or digested (HaeIII or Hinf I)
PCR product size was compared with expected values.18
Preparation of protein extracts for
human skin prick testing and
IgE immunoblot reactivity
Maize and soya protein extracts were made by Laboratorios Leti,
SL (Madrid, Spain) according to approved pharmaceutical prepara-
tive and safety procedures for the production of diagnostic skin prick
test (SPT) materials. About 10 g of each of the maize and soya flour
samples was extracted for 16 hours in 1:20 (wt/vol) PBS (pH 7.4).
After centrifugation, the pellet was discarded, and the supernatant
was extensively dialyzed against bidistilled water. The extracts were
centrifuged, filter sterilized, and freeze-dried. For human SPTs, the
extracts were resuspended to 10 mg/mL maize or soya freeze-dried
material (approximately 2mg of total protein/mL forMON810, Bt11,
Bt176, and control samples; approximately 3 mg of total protein/mL
for T25 and control samples; and approximately 3.5 mg of total
protein/mL for Roundup Ready [RUR] and control samples).
For the IgE immunoblot reactivity assay conducted with sera from
patients with food allergy, we used an extract prepared with food to
which the person undergoing the test was allergic as a positive control
extract. Four grams of food material was homogenized in liquid
nitrogen and precipitated with 20 mL of 10% trichloroacetic acid
(wt/vol) in cold acetone containing 20 mM dithiothreitol for 1 hour at
220C. The precipitate was collected by means of centrifugation
(15 minutes at 14,000g at 4C), washed twice with 20 mM dithio-
threitol in cold acetone, and allowed to dry completely.
Quality of transgenic proteins in maize
and soya extracts
ELISA GMO Check Bt maize test kit (SDI Europe, London,
United Kingdom) was used to evaluate the presence-absence of
Bt CryIA(b) protein in the lyophilized extracts prepared by
Laboratorios Leti. Ten milligrams of dry extract was resuspended
in 200 mL of the kit extraction buffer provided, and all nonsoluble
material was removed by means of centrifugation (10 minutes at
11,000g). The manufacturer’s instructions were followed thereafter,
using approximately 200 mg of total protein.
To evaluate the presence or absence of CP4 5-enolpyruvylshiki-
mate-3-phosphate synthase (CP4EPSPS) protein in RUR soya and
nontransgenic analogues, the lyophilized materials were tested with
an ELISA GMO Check RUR Soya Grain test kit (Strategic Diag-
nostics Inc). Five milligrams of dry extract was diluted in 200 mL of
kit extraction buffer. The nonsoluble material was removed bymeans
of centrifugation (10 minutes at 11,000g). The manufacturer’s
instructions were followed thereafter, using approximately 2.5 mg
of total protein.
Thirty micrograms of each sample was also run by means of
SDS-PAGE and immunobloted with rabbit anti-Bt CryIA(b) poly-
clonal antibodies (RDI, Flanders, NJ) or goat anti-CP4EPSPS serum
(Monsanto Co, St Louis, Mo; see description below).
It was impossible to obtain commercial anti-phosphinotricine
acetyl transferase (anti-PAT) antibodies, and there is no commercially
available ELISAkit for PAT.We therefore decided to use the Trait LL
corn grain test kit (Strategic Diagnostics Inc) to evaluate the presence
or absence of PAT inBt176, Bt11, T25, and nontransgenic analogues.
This kit uses PAT-specific antibodies coupled to a color reagent and
incorporated into strips, allowing the detection of PAT in an extractthrough color development. Ten milligrams of lyophilized samples
was diluted in the kit buffer provided, and 100 mL of each sample
(approximately 200 mg of total protein) was eluted along the strip.
For protein quantification, the Bio-Rad protein assay (Bio-Rad
laboratories) was used, with turkey albumin (Merck) as a standard.
Skin testing of the 2 populations
Skin tests were performed in 2 human populations with positive
histories of food allergy, inhalant allergy, or both, as well as a
positive SPT response for related allergens; one group was composed
of 27 children with food and inhalant allergy from the Paediatrics
Allergy Department of the Hospital of SantaMaria, and the other was
composed of 50 patients with asthma-rhinitis from the University
Clinic of Pneumology from the Hospital of Santa Maria (see Tables
E1 and E2 in the Online Repository in the online version of this
article at www.mosby.com/jaci). The children were tested with the
extracts of Bt176, Bt11, RUR, and nontransgenic analogues; for the
asthma-rhinitis population, we used the extracts of MON810, T25,
and nontransgenic analogues for testing (Table I).
Skin tests were performed by using the prick procedure,19 and
results were read after 20 minutes. The results were classified as
positive when the larger diameter of the wheal exceeded 3 mm.
Histamine hydrochloride, 10 mg/mL (Leti), was used as a positive
control, and Phenolate saline serum with glycerine (Leti) was used as
a negative control.
All the protein extracts were first tested on a control population of
20 nonallergic healthy individuals.
Sera for the IgE immunoblot reactivity assay
Patient sera were provided by the JoaquimChaves Clinic andwere
obtained from 57 individuals who had a positive history of docu-
mented food allergy, as well as a positive value equal to or higher than
class 3 on specific UniCAP test (Pharmacia Diagnostics, Seixal,
Portugal; see Table E3 in the Online Repository in the online version
of this article at www.mosby.com/jaci). All 57 sera were first assayed
for reactivity against nontransgenic maize and soya by means of
specific IgE UniCAP testing. The sera were then tested for IgE
immunoblot reactivity against Bt11, Bt176 maize, and RUR soya, as
well as against nontransgenic analogues (Table I). MON810 maize
and its nontransgenic analogue, as well as pure CryIA(b) (Research
Diagnostics, Inc) and CP4EPSPS (Monsanto Co), were used to test
the IgE immunoblot reactivity of sera of the 24 more sensitive
patients (Table I).
SDS-PAGE and protein transfer to
nitrocellulose membranes
Samples were diluted 1:2 in sample buffer (0.125M Tris-HCl [pH
6.8], 4% SDS, 20% vol/vol glycerol, 0.2 M dithiothreitol, and 0.02%
bromophenol blue) and boiled for 5 minutes before electrophoresis
in a 0.75-mm-thick 10% acrylamide gel with 4% stacking gel.20 After
electrophoresis, the proteins were blotted onto hybond ECL nitro-
cellulose membranes (Amersham Biosciences, Carnaxide, Portugal)
by means of wet transfer in 25 mMTris, 192 mM glycine, 0.1% SDS,
and 20% methanol for 1 hour at 75V at room temperature.
IgE immunoblot reactivity assay of sera
from patients with food allergy
The detection of patient sera IgE reactivity was carried out after
electrophoresis of 30 mg (60 mg/cm gel width) of MON810, Bt11,
Bt176, and RUR transgenic samples and nontransgenic analogues
and 25 ng (50 ng/cm gel width) of pure CryIA(b) and CP4EPSPS and
transfer to nitrocellulose membrane.
Blots were blocked overnight at 4C with PBS-T (58 mM
Na2HPO4, 17 mM NaH2PO4.H2O, 68 mM NaCl, and 0.2% Tween
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isTABLE II. Results of the food inquiry regarding the probability of an individual having consumed a transgenic maize
or soya sample
Mean number of consumed
products with maize or soya
(l estimates)
Probability of consumption of products
with transgenic protein
n 95% CI P = .235 95% CI
Total 106 39.3 35.2-43.4 0.999902 0.99974-0.99999
Sex
Male 48 34.8 29.2-40.4 0.999959 0.99895-0.99993
Female 58 43.0 37.1-48.2 0.999719 0.99983-0.99999
Age group (y)
<5 20 29.5 22.6-36.3 0.999024 0.99506-0.99980
5-10 56 41.1 35.2-46.9 0.999936 0.99974-0.99998
10-25 11 48.8 35.6-62.0 0.999990 0.99976-1.00000
25 19 38.9 27.5-50.3 0.999893 0.99844-0.99999
n, Number of valid responses; P, probability of one product with maize or soya having transgenic proteins (Instituto de Biologia Experimental e
Tecnolo´gica Good Laboratory Practices Microbiology laboratory data).20) and 5% skimmedmilk powder (or 3%BSA for patients with milk
allergy) and washed with PBS-T before incubation in serum diluted
1:10 in blocking solution for 1 hour and 30 minutes at room
temperature. After washing with PBS-T, the membranes were
incubated for 1 hour at room temperature in alkaline phosphatase–
conjugated monoclonal anti-human IgE (Southern Biotechnology
Associates, Birmingham, Ala) diluted 1:2000 in blocking solution,
washed with PBS-T and assay buffer, and incubated for 5 minutes
with CDP-Star solution with Nitro-Block II enhancer (Tropix
Western-Star Immunodetection System).
Blots were observed after exposure (5 seconds-30 minutes) to a
high-performance chemiluminescence Hyperfilm ECL (Amersham
Biosciences).
Immunoblot detection of Bt CryIA(b)
and CP4EPSPS
The procedure was identical to the one described for IgE
immunobloting of patient’s sera, with the following differences. For
Bt CryIA(b), the first antibody incubation was performed in rabbit
anti-Bt CryIA(b) polyclonal (Research Diagnostics, Inc) diluted
1:1400 in blocking solution, and the second antibody incubation
was performed in goat anti-rabbit IgG-AP conjugate (Tropix-Applied
Biosystems, Porto, Portugal) diluted 1:2800 in blocking solution. For
CP4EPSPS, the first antibody incubation was performed in goat anti-
CP4EPSPS serum (Monsanto Co) diluted 1:5000 in blocking solu-
tion, and the second antibody incubation was performed in anti-goat
IgG-alkaline phosphatase conjugate (Sigma, Sintra, Portugal) diluted
1:2500 in blocking solution.
Statistical analysis
To estimate the probability of one individual from the Portuguese
population having once been in contact with transgenic proteins
present in maize or soya foods, we used (1) the results from the food
inquiry and (2) the percentage data of maize and soya products with
detectable transgenic proteins provided by Instituto de Biologia
Experimental e Tecnolo´gica Good Laboratory Practices Microbiol-
ogy laboratory. This laboratory is one of the 2 national laboratories
responsible for food GMO detection.
Assuming that the number of products with maize or soya
consumed by the population is a Poisson random variable with the
expected value l and that the probability of an individual having
consumed a product with transgenic proteins (provided he or she had
consumed n products with maize or soya) is modeled by using
binomial distributions21 (n = number of experiences, p = probabilityof one product withmaize or soya having transgenic proteins), we can
then calculate the probability of one individual having been in contact
with transgenic proteins, which is 12e2lp.
To estimate this probability, we used as l the mean number of
consumed products with maize or soya obtained in the survey, and as
p the proportion of maize and soya products detected with transgenic
proteins calculated by using the Instituto de Biologia Experimental e
Tecnolo´gica Good Laboratory Practices Microbiology laboratory
data during the last 2 years.
RESULTS
Food inquiry
All 106 individuals participating in this inquiry con-
sumed some of the 205 products presented. The extreme
cases, with lower and higher numbers of consumed
products, were relative to a 1-year-old and 9-year-old
girl with 4 and 129 consumed products, respectively.
The mean of consumed products with maize and soya
was 39.3 (95% CI, 35.2-43.4), and the probability of
an individual having eaten GM food was near 100%
(Table II).
Transgenic quality of the noncertified
flour samples
All 6 tested samples (Bt176, T25, MON810, and the
nontransgenic analogues) showed the expected bands
when checking for amplifiable maize DNA (data not
shown), and only the 3 transgenic samples showed the
expected amplicon of the 35S promoter (data not shown).
The final confirmation that all the samples tested were
correctly labeled and that there was no cross-contamina-
tion among them was obtained from construct-specific
PCR (Fig 1). As expected, the digestion of the obtained
amplicons confirmed the accuracy of the specific PCR
(data not shown).
Quality of transgenic proteins in maize
and soya extracts
As described in the Methods section, Laboratorios
Leti protein extracts were tested for the presence of the
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isFIG 1. Construct-specific PCR for the detection of modified DNA sequences from T25, Bt176, and MON810
maize.M, 100-bp DNA ladder;MM, Mastermix; Bl, DNA extraction blank; T252, Bt1762, MON8102, non-GM
controls; T251, Bt1761, MON8101, 100% GM T25, Bt176, and MON810 maize, respectively.
FIG 2.Western blot for the detection of CryIA(b) protein in Laboratorios Leti protein extracts. I, 10%Acrylamide
SDS-PAGE; II, immunoblot with rabbit anti-Bt CryIA(b) polyclonal. M, Molecular weight marker; Bt112,
MON8102, Bt1762, non-GM controls; Bt111, MON8101, Bt1761, GM material 2% Bt11, 100% MON810, and
100% Bt176, respectively.Fo
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stransgenic proteins under testing. CryIA(b) was detected
by using ELISA (data not shown) and Western blotting
(Fig 2) in MON810, Bt11, and Bt176 extracts and
was absent from the nontransgenic control analogues.
CP4EPSPS was also detected by means of ELISA (data
not shown) and Western blotting (Fig 3) in RUR ex-
tract and was absent from the nontransgenic analogue.
Both pure CryIA(b) and CP4EPSPS proteins were de-
tected with the respective specific antibodies (data not
shown).
In T25, Bt11, and Bt176 samples PAT protein was
detected in 200 mg of total protein solutions by using theTrait LL corn grain test kit. With this system, we have also
confirmed the absence of PAT in nontransgenic analogues
(data not shown).
Allergenicity tests
Skin testing of the 2 populations. Only individuals
with maize sensitivity, soybean sensitivity, or both had
positive results against the protein extracts under testing;
however, none of the volunteers reacted differentially to
GM versus non-GM samples (Table III and Tables E1 and
E2 in the Online Repository in the online version of this
article at www.mosby.com/jaci).
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isFIG 3. Western blot for the detection of CP4EPSPS protein in Laboratorios Leti protein extracts. I, 10%
Acrylamide SDS-PAGE; II, immunoblot with anti-CP4EPSPS goat serum (IgG). M, Molecular weight marker;
Bt112, Bt1762, RUR2, non-GM controls; Bt111, Bt1761, RUR1, GM material 2% Bt11, 100% Bt176, and
5% RUR, respectively.All the patients had wheals larger than 3 mm for
histamine, and none of them reacted against the negative
control.
IgE Immunoblot reactivity assay of sera from
patients with food allergy. Two types of Western
blotting results (Figs 4 and 5) were observed. In Fig 4
serum from an individual with octopus allergy of class 4
on specific UniCAP testing reacted only against positive
controls. In Fig 5, concerning an individual with peanut
allergy of class 6 on a specific UniCAP test, positive
signals were observed against the positive control but also
against other maize and soya protein extracts.
None of the volunteers tested presented differential
signals against nontransgenic versus transgenic protein
extracts (Table III). All 24 individuals tested against pure
transgenic proteins (CP4EPSPS and CryIAb) presented no
detectable reactions against these controls.
DISCUSSION
Although absolute certainties regarding GM food risks
to health and the environment will hardly be obtained,
reports regarding potential problems have raised public
concern. Some of the concerning issues include the
putative toxicity-allergenicity of crops expressing foreign
proteins,22-25 although these fears have not been con-
firmed in some later studies,26,27 and the adequacy of the
TABLE III. Results obtained with the allergenicity
tests performed by using SPTs and IgE immunoblot
reactivity assays
SPTs
IgE immunoblot
reactivity assay
No. of
individuals
tested
Positive
responses
(%)
No. of
individuals
tested
Positive
responses
(%)
GM protein
PAT 77 0 NT 2
CRY1A(b) 77 0 57 0
CP4EPSPS 27 0 57 0
NT, Not tested.methods of testing have been questioned.28 Considering
that the past few decades have witnessed a significant
increase in IgE-mediated allergic diseases, the allergenic
potential of these novel foods is a major concern in public
health.
The food inquiry performed in this study indicated that
the probability of an individual having eaten GM food was
near 100% (Table II). This value is probably underesti-
mated because each individual probably consumed each
product several times, which was not considered in statis-
tical calculations.
Also, it is possible that the first sensitization occurred
during breast-feeding in the individuals submitted to SPTs
and Western blot analyses who were younger than 6 years
(the time between the first commercialization in 1998 and
2004).29 It therefore seems reasonable to assume that all
the individuals participating in this study had already been
in contact with the products tested.
The DNA and protein quality analysis performed in this
study confirmed the quality of flour samples and maize
and soya protein extracts (Figs 1-3). In the Western assay
for the detection of CryIA(b) in Bt11, Bt176, MON810,
and nontransgenic control analogues (Fig 2), the multiple
bands approximately equal to the CryIA(b) trypsin resis-
tant core observed are likely the products of endogenous
grain proteases.30 Some of the protein is degraded further
to produce lower-molecular-weight bands, including a
30-kd product previously reported.30
As already mentioned, we have performed this study on
sensitive populations. The population submitted to SPTs
and immunoblot analyses was composed of individuals
with food allergy and inhalant allergy, many of them
children. Children are more susceptible to food allergies
than adults. This higher susceptibility is probably the
result of immunologic immaturity and, to some extent,
immaturity of the gut.31,32 In addition, children who have
preexisting food allergies are more likely to experience
allergic reactions to other foods introduced in their diets.
The absence of detectable differences in IgE reactivity
between GMmaize and soya samples and the correspond-
ing wild-type samples obtained in this study is in accor-
dance with some previously published results.33,34
The appearance of nondifferential bands on some
chemiluminescence films for maize and soya protein
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isFIG 4. IgE antibody reactivity assay from an octopus-sensitive patient. I, 10% Acrylamide SDS-PAGE;
II, immunoblot. M, Molecular weight marker; Bt112, Bt1762, RUR2, MON8102, non-GM controls; Bt111,
Bt1761, RUR1, MON8101, GM material 2% Bt11, 100% Bt176, 5% RUR, and 100% MON810, respectively;
Otp, Octopus protein extract; Cry, CryIA(b); CP4, CP4EPSPS.
FIG 5. IgE antibody reactivity assay from a peanut-sensitive patient. I, 10% Acrylamide SDS-PAGE;
II, immunoblot. M, Molecular weight marker; Bt112, Bt1762, RUR2, non-GM controls; Bt111, Bt1761,
RUR1, GM material 2% Bt11, 100% Bt176, and 5% RUR, respectively; Pnt, Peanut protein extract.Fo
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cross-reactivity among various plant and animal pro-
teins.35,36 In the example presented in Fig 5, although
the patient tested had only documented peanut allergy
(class 6 on UniCAP test), it was shown that he also had
IgE binding to other foods, such as almond (class 2),
hazelnut (class 3), walnut (class 2), cashew (class 4),
soybean (class 3), and maize (class 3). This fact justifies
the appearance of the nondifferential bands on maize and
soya lanes.
Although IgE detection (either SPT or specific IgE)
serves as a good indicator of sensitization but not neces-
sarily of disease, in the clinical setting the absence of
detectable IgE was found to have excellent negative pre-
dictive accuracy indices and therefore might be very
useful in excluding the presence of immediate food hyper-
sensitivity.37In this study we did not obtain any differential positive
results, which allows us to conclude that the transgenic
products under testing seem to be safe regarding their
allergenic potential. Although we succeeded in integrating
a private clinic and a hospital in this study, it would be
desirable to increase the size of the analyzed population
and eventually extend this work to other countries.
We also propose the development and use of clinical
testing with specific IgE in the postmarketing surveillance
of foods produced through biotechnology. Positive test
results should be followed by double-blind, placebo-
controlled food challenges under appropriate clinical
observation to identify true clinical reactions.38
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